Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.
|Published (Last):||12 July 2014|
|PDF File Size:||9.68 Mb|
|ePub File Size:||1.77 Mb|
|Price:||Free* [*Free Regsitration Required]|
Fortis again pushes back date to complete RHT Health deal; auditor resigns. The company is engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
Here’s how the world is celebrating Christmas. Promoter Satish Ramanlal Mehta holds In AprilEmcure acquired Heritage Pharmaceuticals, a New Jersey-based generic pharmaceutical company, which provided it a commercial platform to market and sell its products.
These areas include wmcure, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients.
Blackstone to sell its stake in Emcure to Bain
Will be displayed Will not be displayed Will be displayed. Technicals Technical Chart Visualize Screener. BSCPL is an infrastructure development company which operates in road, irrigation, real estate and hydro power projects. Blackstone has invested Rs crore in Emcure through convertible shares and currently holds a Log in Keep me signed in.
Emcure is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Emcure Pharmaceuticals withdraws proposed IPO. Drag according to your convenience. Your Reason has been Reported to the admin. It is ranked as the 7th-largest pharmaceutical company in the therapeutic areas in which it operates. Warren Buffett has this piece of advice for youngsters and it’s not stocks.
The firm is now evaluating options for an offshore listing. Emcure is ranked as the 14th-largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products. Infibeam calls off pact to acquire Snapdeal unit Unicommerce.
Blackstone to sell its stake in Emcure to Bain – Livemint
Private equity major Blackstone has started the process of exiting its maiden investment in India, Emcure Pharmaceuticals. It has subsidiaries in Brazil, DubaiNigeria, Singapore and South Africa and branch offices in Morocco and Russiawhich play an important role in its international operations, the release said. This will alert our moderators to take action Name Reason for reporting: Mandhana added that while an IPO is a convenient route for exits, secondary transactions provide more comfort to the new investor as potential corporate governance issues would have already been taken care of by the exiting PE firm.
Blackstone had invested Rs crore in Emcure through erhp shares and held This follows a deal drhl late last year drhhp Blackstone sold its stake to Bain Capital for an undisclosed amount.
The PE firm is selling around 1. Leave Your Comment s.
Choose your reason below and click on the Report button. Edited by Joby Puthuparampil Johnson. Emcure is ranked among the top 15 pharmaceutical companies in India in terms of market share based on the domestic sales of pharmaceutical products.
Fri, Dec 20 From Berlin to Washington: Emcure operates nine manufacturing facilities, eight of which are located in India and one in the United Emcute. The transaction is subject to conditions under contract and law including Foreign Investment Promotion Board approval.
Emcure Pharmaceuticals withdraws proposed IPO | VCCircle
Ltd with returns of almost three times. To see your saved stories, click on link hightlighted in bold. Never miss a great news story! Antibiotics made by Emcure Pharmaceuticals recalled in US. My Saved Articles Sign in Sign up. Crude oil prices to direct sugar prices in Secondary transactions set the ground for appropriate valuations as there is no information arbitrage unlike in a primary transaction. Another pharmaceutical firm which filed for public offering recently was Intas Pharmaceuticals.
Emcure Pharmaceuticals withdraws proposed IPO
Fill in your details: Link Intime India Private Limited is a registrar to the issue. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol. Pune-based Emcure Pharmaceuticals has pulled out its proposed initial public offer IPO which was to raise around Rs crore besides giving part exit to Blackstone in its maiden investment in India.
The issue also involves a secondary xrhp 2. This will alert our moderators to take action. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus DRHP with SEBI for initial public offering that includes fresh issue of upto Rs crore and an offer for sale of upto 25,13, equity share. Book running lead managers to the issue include Bank of America Merrill Lynch.